Sovran Advisors LLC Trims Holdings in Pfizer Inc. $PFE

Key Points

• Sovran Advisors LLC reduced its holdings in Pfizer Inc. by 76.5% during Q2, selling 25,471 shares and ending with 7,816 shares valued at $200,000.
• Wall Street analysts are generally optimistic about Pfizer, with an average rating of "Hold" and a consensus price target of $28.12, reflecting recent price objective increases from multiple firms.
• Pfizer recently declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 7.2%, with a dividend payout ratio of 91.49%.

Sovran Advisors LLC reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 76.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,816 shares of the biopharmaceutical company's stock after selling 25,471 shares during the period. Sovran Advisors LLC's holdings in Pfizer were worth $200,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter valued at $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Bank of America lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Trading Up 0.1%

Shares of PFE traded up $0.02 during trading hours on Monday, hitting $24.05. The company had a trading volume of 67,725,099 shares, compared to its average volume of 45,384,523. The firm has a market cap of $136.74 billion, a P/E ratio of 12.79, a P/E/G ratio of 0.78 and a beta of 0.55. The stock's 50 day moving average price is $24.63 and its 200 day moving average price is $24.20. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer's payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.